8-K current report · filed Jul 15, 2026

GYRE THERAPEUTICS, INC. (GYRE) 8-K Current Report: July 15, 2026

Item EX-99.1Item EX-99.2Item 2.02GYRE overview

Short answer

GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on July 15, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Amendment adds Cullgen financial statements through March 31, 2026 and December 31, 2025.

GYRE THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Amendment adds Cullgen financial statements through March 31, 2026 and December 31, 2025
  • Pro forma combined balance sheet for Gyre and Cullgen as of March 31, 2026
  • Pro forma combined operating results cover three months ended March 31, 2026 and year ended December 31, 2025
  • Investors gain updated post-transaction financial visibility into the combined company

Item EX-99.1 · Exhibit EX-99.1

  • Audited Cullgen financial statements received an unqualified opinion under U.S. GAAP for year ended December 31, 2025
  • Cash and short-term investments totaled $40.2 million against $21.0 million operating cash burn
  • Accumulated deficit reached $132.2 million, with $10.8 million net loss and no product-sales revenue
  • Collaboration revenue totaled $15.4 million, all from one customer, creating significant revenue concentration
  • Redeemable preferred stock had a $116.0 million liquidation preference, senior to common equity holders

Item EX-99.2 · Exhibit EX-99.2

  • Cullgen merger closed May 4, 2026 in an all-stock transaction valued at approximately $300 million
  • Pro forma combined assets $206.6 million, including Gyre cash $37.5 million and Cullgen cash $13.3 million
  • Pro forma revenue $24.4 million and net loss $18.6 million for Q1 2026
  • Pro forma 2025 revenue $132.0 million, with net loss available to common stockholders of $6.1 million
  • Merger issued 14,450,527 Gyre common shares, increasing pro forma basic shares to 103,795,149 in 2025 and diluting existing holders

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other GYRE THERAPEUTICS, INC. 8-K filings

Get the next GYRE 8-K as it lands

Follow GYRE for push alerts, or ask the research agent what this filing means.